Journal Article

Rapid Multiplexed Proteomic Screening for Primary Immunodeficiency Disorders From Dried Blood Spots

Ochs, Hans D., Dayuha, Remwilyn, Segundo, Gesmar R. S., Hahn, Si Houn, Collins, Christopher J., Torgerson, Troy R., Paulovich, Amanda G., Jung, Sunhee, Chang, Irene J., Whiteaker, Jeffrey R.

2018

Overview

Primary immunodeficiency disorders (PIDD) comprise a group of life-threatening congenital diseases characterized by absent or impaired immune responses. Despite the fact that effective, curative treatments are available with optimal clinical outcomes when diagnosed early, newborn screening does not exist for the majority of these diseases due to the lack of detectable, specific biomarkers or validated methods for population-based screening. Peptide immunoaffinity enrichment coupled with selected reaction monitoring mass spectrometry (immuno-SRM) is a sensitive proteomic assay, involving antibody-mediated peptide capture, that allows for concurrent quantification of multiple analytes. This assay has promise for use in potential newborn screening of PIDDs that lead to diminished or absent target proteins in the majority of cases. To determine and evaluate if a multiplex assay based on immuno-SRM is able to reliably and precisely distinguish affected patients with X-linked agammaglobulinemia (XLA), Wiskott-Aldrich Syndrome (WAS), and CD3ϵ-associated severe combined immunodeficiency (SCID) from one another and from unaffected normal control dried blood spot (DBS) samples. We performed a blinded, multiplexed analysis of proteolytically-generated peptides from WASp, BTK, and CD3ϵ (for WAS, XLA, and SCID, respectively) in DBS samples from 42 PIDD patients, 40 normal adult controls, and 62 normal newborns. The peptide ATPase copper transporting protein (ATP7B) 1056 was simultaneously monitored for quality assurance purposes. The immuno-SRM assays reliably quantified the target peptides in DBS and accurately distinguished affected patients from normal controls. Analysis of signature peptides found statistically significant reduction or absence of peptide levels in affected patients compared to control groups in each case (WASp and BTK: = 0.0001, SCID: = 0.05). Intra and inter-assay precision ranged from 11 to 22% and 11 to 43% respectively; linearity (1.39-2000 fmol peptide), and stability (≤ 0.09% difference in 72 h) showed high precision for the multiplexed assay. Inter-laboratory assay comparison showed high concordance for measured peptide concentrations, with R linearity ≥ 0.97 for the WASp 274, CD3ϵ 197, BTK 407, and ATP7B 1056 peptides. Immuno-SRM-based quantification of proteotypic peptides from WASp, BTK, and CD3ϵ in DBS distinguishes relevant PIDD cases from one another and from controls, raising the possibility of employing this approach for large-scale multiplexed newborn screening of selective PIDDs.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: Acids / Agammaglobulinemia / Agammaglobulinemia - diagnosis / Agammaglobulinemia - metabolism / Antibodies / Antibodies - metabolism / Biological Assay - methods / Biomarkers / Biomarkers - metabolism / Children & youth / Chromatography / Chromatography, Liquid - methods / Cohort Studies / Copper-Transporting ATPases - metabolism / Dried Blood Spot Testing - methods / Enzymes / Female / Genetic Diseases, X-Linked - diagnosis / Genetic Diseases, X-Linked - metabolism / Humans / Immune response / Immune system / Immunologic Deficiency Syndromes - diagnosis / Immunologic Deficiency Syndromes - metabolism / Immunology / Infant, Newborn / Laboratories / Mass spectrometry / Mass Spectrometry - methods / Mass spectroscopy / Medical screening / Metabolites / Mutation / Neonatal Screening - methods / Neonates / Patients / peptide immunoaffinity enrichment coupled to SRM (immuno-SRM) / Peptides / Peptides - metabolism / Primary immunodeficiencies / Primary Immunodeficiency Disorders (PIDD) / Protein transport / Proteins / Proteomics / Proteomics - methods / Quality assurance / Scientific imaging / Severe combined immunodeficiency / Severe Combined Immunodeficiency (SCID) / Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) / Statistical analysis / Wiskott-Aldrich syndrome / Wiskott-Aldrich Syndrome (WAS) / X-linked agammaglobulinemia / X-linked Agammaglobulinemia (XLA)